- Home
- LNZA vs TVRD Comparison
LNZA vs TVRD Comparison
Compare LNZA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | TVRD |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 37.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LNZA | TVRD |
|---|---|---|
| Price | $13.09 | $4.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $14.00 | ★ $51.67 |
| AVG Volume (30 Days) | 8.3K | ★ 123.2K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $113.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.20 | $3.74 |
| 52 Week High | $274.00 | $43.65 |
Technical Indicators
Market Signals| Indicator | LNZA | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 35.74 |
| Support Level | $13.05 | $3.90 |
| Resistance Level | $14.36 | $4.05 |
| Average True Range (ATR) | 1.06 | 0.23 |
| MACD | 0.01 | 0.24 |
| Stochastic Oscillator | 6.53 | 34.09 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.